Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions

International Immunology

Volumn 21, Issue 6, 2009, Pages 655-665

  Mortara, Lorenzo ^a   Frangione, Valeria ^a   Castellani, Patrizia ^b   De Lerma Barbaro, Andrea ^a   Accolla, Roberto S ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

CIITA; CTL; MHC class II; Th cells; Treg cells

Indexed keywords

CANCER VACCINE; TS A MHC CLASS II TRANSCRIPTIONAL ACTIVATOR VACCINE; TS A PARENTAL CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; RADIATION; T-LYMPHOCYTE SUBSETS; TRANS-ACTIVATORS; TRANSFECTION;

EID: 66249115636     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxp034     Document Type: Article

References (32)

1. Dunn, J. P., Old, L. J. and Schreiber, R. D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329.
2. Dudley, M. E. and Rosenberg, S. A. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3:666.
3. Rosenberg, S. A., Yang, J. C. and Restifo, N. P. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10:909.
4. Smyth, M. J., Dunn, G. P. and Schreiber, R. D. 2006. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90:1.
5. Lollini, P. L., Cavallo, F., Nanni, P. and Forni, G. 2006. Vaccines for tumour prevention. Nat. Rev. Cancer 6:204.
6. Ossendorp, F., Mengede, E., Camps, M., Filius, R. and Melief, C. J. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
7. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
8. + T-helper and a T-killer cell. Nature 393:474.
9. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88.
10. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R. 1998. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature 393:478.
11. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
12. Rabinovich, G. A., Gabrilovich, D. and Sotomayor, E. M. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25:267.
13. + regulatory T cells for immunologic self-tolerance and negative control of the immune response. Annu. Rev. Immunol. 22:531.
14. Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. 2008. Cancer-related inflammation. Nature 454:436.
15. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. and Bronte, V. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222:162.
16. Berzofsky, J. A. and Terabe, M. 2008. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180:3627.
17. Meazza, R., Comes, A., Orengo, A. M., Ferrini, S. and Accolla, R. S. 2003. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur. J. Immunol. 33:1183.
18. Mortara, L., Castellani, P., Meazza, R. et al. 2006. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin. Cancer Res. 12:3435.
19. Huang, A. Y., Gulden, P. H., Woods, A. S. et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl Acad. Sci. USA 93:9730.
20. Nanni, P., De Giovanni, C., Lollini, P. L., Nicoletti, G. and Prodi, G. 1983. TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1:373.
21. Mortara, L., Balza, E., Sassi, F. et al. 2007. Therapy-induced antitumor vaccination by targeting tumor necrosis factor-a to tumor vessels in combination with melphalan. Eur. J. Immunol. 37:3381.
22. Sun, Y., Paschen, A. and Schadendorf, D. 1999. Cell-based vaccination against melanoma: Background, preliminary results, and perspectives. J. Mol. Med. 77:593.
23. Henderson, R. A., Mossman, S., Nairn, N. and Cheever, M. A. 2005. Cancer vaccine and immunotherapies: Emerging perspectives. Vaccine 23:2359.
24. Ostrand-Rosenberg, S., Pulaski, B. A., Clements, V. K., Qi, L., Pipeling, M. R. and Hanyok, L. A. 1999. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol. Rev. 170:101.
25. Gilboa, E. 2007. DC-based cancer vaccines. J. Clin. Inv. 117:1195.
26. + T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol. 176:1447.
27. Kim, D., Hoory, T., Monie, A., Ting, J. P. Y., Hung, C. F. and Wu, T. C. 2008. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J. Immunol. 180:7019.
28. + T cell responses in anti-tumor immunity. Curr. Opin. Immunol. 10:588.
29. Wang, R. F. 2002. Enhancing antitumor immune response: Intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. 188:65.
30. Lopez, M. V., Adris, S. K., Bravo, A. I., Chernajovsky, Y. and Podhajcer, O. L. 2005. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J. Immunol. 175:5885.
31. Schuler, T., Qin, Z., Ibe, S., Noben-Trauth, N. and Blankenstein, T. 1999. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J. Exp. Med. 189:803.
32. Balza, E., Mortara, L., Sassi, F. et al. 2006. Targeted delivery of tumor necrosis factor-a to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 12:2575.